David P. Kelsen

Active 1978–2025

153
Papers
31,683
Citations
97
h-index
151
i10-index

Citations

Citations per year for David P. Kelsen1980: 1 citations1981: 2 citations1982: 5 citations1983: 17 citations1984: 11 citations1985: 14 citations1986: 12 citations1987: 20 citations1988: 19 citations1989: 27 citations1990: 22 citations1991: 38 citations1992: 30 citations1993: 41 citations1994: 46 citations1995: 61 citations1996: 63 citations1997: 86 citations1998: 71 citations1999: 108 citations2000: 89 citations2001: 103 citations2002: 141 citations2003: 124 citations2004: 127 citations2005: 144 citations2006: 153 citations2007: 143 citations2008: 139 citations2009: 113 citations2010: 109 citations2011: 161 citations2012: 94 citations2013: 105 citations2014: 106 citations2015: 198 citations2016: 200 citations2017: 256 citations2018: 243 citations2019: 848 citations2020: 921 citations2021: 944 citations2022: 694 citations2023: 542 citations2024: 798 citations2025: 393 citations2026: 19 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,877 citing papers, 27% of this breakdownChina: 1,684 citing papers, 15.8% of this breakdownJapan: 620 citing papers, 5.8% of this breakdownUnited Kingdom: 585 citing papers, 5.5% of this breakdownItaly: 525 citing papers, 4.9% of this breakdownGermany: 522 citing papers, 4.9% of this breakdownSouth Korea: 380 citing papers, 3.6% of this breakdownFrance: 335 citing papers, 3.1% of this breakdownNetherlands: 315 citing papers, 3% of this breakdownCanada: 265 citing papers, 2.5% of this breakdownSpain: 198 citing papers, 1.9% of this breakdownAustralia: 184 citing papers, 1.7% of this breakdown
0%27%Other 20.3%

Fields

  • Medicine73.3%
  • Biochemistry, Genetics and Molecular Biology21.6%
  • Immunology and Microbiology2.2%
  • Neuroscience0.7%
  • Computer Science0.6%
  • Engineering0.3%
  • Other1.3%

Topics

  • Gastric Cancer Management and Outcomes7.1%
  • Esophageal Cancer Research and Treatment4.8%
  • Pancreatic and Hepatic Oncology Research4.7%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Cancer Genomics and Diagnostics3.2%
  • Colorectal Cancer Treatments and Studies2.2%
  • Other74.1%

Coauthors

All papers

Open in search
  1. Comprehensive molecular characterization of gastric adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ricardo Ramírez, Chris Sander, S. Onur Sumer, Rileen Sinha, William Lee, Giovanni Ciriello, Yichao Sun, Nikolaus Schultz, Ronglai Shen, Yelena Y. Janjigian, David P. Kelsen, David P. Kelsen, Haiyan A. Li, Amanda Clarke, Noreen Dhalla, Andy Chu, Andrew J. Mungall, Justin Chu, Nina Thiessen, Karen Mungall, Emilia L. Lim, Denise Brooks, Reanne Bowlby, Miruna Balasundaram, Darlene Lee, Angela Tam, Richard A. Moore, Hye-Jung E. Chun, Michael Mayo, A. Gordon Robertson, Eric Chuah, Steven J.M. Jones, Rebecca Carlsen, Marco A. Marra, Marco A. Marra, Payal Sipahimalani, Yussanne Ma, Ranabir Guin, Robert A. Holt, Yaron S.N. Butterfield, Ka Ming Nip, Reanne Bowlby, Adrian Ally, Jacqueline E. Schein, İnanç Birol, Lihua Zou, Nils Gehlenborg, Yingchun Liu, Travis Zack, Scott L. Carter, Jaegil Kim, Eric S. Lander, Petar Stojanov, Barbara Tabak, Andrew D. Cherniack, Gordon Saksena, Bradley A. Murray, Rameen Beroukhim, Lee Lichtenstein, Carrie Sougnez, Gad Getz, Chandra Sekhar Pedamallu, Juok Cho, Kristian Cibulskis, David I. Heiman, Doug Voet, Joonil Jung, Sheila Fisher, Hailei Zhang, Scott Frazer and 158 more - Nature 2014 cited by 6,599

  2. Tumour extracellular vesicles and particles induce liver metabolic dysfunction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kelsey Klute, Tanya Trippett, Mikala Egeblad, Doru Paul, Jacqueline Bromberg, David P. Kelsen, Vinagolu K. Rajasekhar, John H. Healey, Irina Matei, William R. Jarnagin, Robert E. Schwartz, Haiying Zhang, David Lyden - Nature 2023 cited by 261

  3. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 357

  4. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura H. Tang, Barry S. Taylor, David B. Solit, Nikolaus Schultz - Cancer Discovery 2017 cited by 382

  5. Artificial Intelligence and Early Detection of Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lawrence H. Schwartz, Uri Shalit, Sudhir Srivastava, Brian M. Wolpin - Pancreas 2021 cited by 150

  6. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 398

  7. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eileen M. O’Reilly - Clinical Cancer Research 2020 cited by 226

  8. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy

    Authors: , , , , , , , , - Journal of Clinical Oncology 2002 cited by 1,130

  9. Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 111

  10. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 82

  11. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

    Authors: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 363

  12. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 107

  13. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease

    Authors: , , , , , , , , , , , , , , , - Gastroenterology 2016 cited by 197

  14. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y. Janjigian - Cancer Discovery 2018 cited by 147

  15. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Madison Friedman, Caroline K. Glidden, Laetitia Firmenich, Grace Lieberman, D. Mejia, Naaz Nasar, Anders P. Mutvei, Doru Paul, Yaron Bram, Bruno Costa‐Silva, Olca Baştürk, Nancy Boudreau, Haiying Zhang, Irina Matei, Ayuko Hoshino, David P. Kelsen, Irit Sagi, Avigdor Scherz, Ruth Scherz‐Shouval, Yosef Yarden, Moshe Oren, Mikala Egeblad, Jason S. Lewis, Kayvan R. Keshari, Paul M. Grandgenett, Michael A. Hollingsworth, Vinagolu K. Rajasekhar, John H. Healey, Bergþór Björnsson, Diane M. Simeone, David A. Tuveson, Christine A. Iacobuzio–Donahue, Jaqueline Bromberg, C. Theresa Vincent, Eileen M. O’Reilly, Ronald P. DeMatteo, Vinod P. Balachandran, Michael I. D’Angelica, T. Peter Kingham, Peter J. Allen, Amber L. Simpson, Olivier Elemento, Per Sandström, Robert E. Schwartz, William R. Jarnagin, David Lyden - Nature Medicine 2024 cited by 54

  16. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

    Authors: , , , , , , , , , , , - Annals of Oncology 2012 cited by 367

  17. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 51

  18. Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

    Authors: , , , , , - CA A Cancer Journal for Clinicians 2017 cited by 309

  19. Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher E. Mason - iScience 2020 cited by 56

  20. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

    Authors: , , , , , - Diseases of the Esophagus 2016 cited by 279

  21. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth Offit, Zsofia K. Stadler, Eileen M. O’Reilly - JNCI Journal of the National Cancer Institute 2018 cited by 224

  22. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine

    Authors: , , , , , , , , , , , , , , , , , , - Radiology 2018 cited by 106

  23. Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids

    Authors: , , , , , , , , , , , , , , , , , , , , , - STAR Protocols 2020 cited by 40

  24. Molecular Classification of Gastric Cancer: A New Paradigm

    Authors: , , , , , , - Clinical Cancer Research 2011 cited by 314